Skip to main content
News Icon

News categories: Publication

Genetic disposition protects immune system from aging

A genetic disposition that plays a role in the development of the heart in the embryo also appears to play a key role in the human immune system. This is shown by a recent study led by the University of Bonn. When the gene is not active enough, the immune defense system undergoes characteristic changes, causing it to lose its effectiveness. Doctors speak of an aging immune system, as a similar effect can often be observed in older people. In the medium term, the results may contribute to reduce these age-related losses. The study is published in the journal Nature Immunology.

The gene with the cryptic abbreviation CRELD1 has so far been a mystery to science. It was known to play an important role in the development of the heart in the embryo. However, CRELD1 remains active after birth: Studies show that it is regularly produced in practically all cells of the body. For what purpose, however, was previously completely unknown.

The Bonn researchers used a novel approach to answer this question. Nowadays, scientific studies with human participants often include so-called transcriptome analyses. By these means, one can determine which genes are active to what extent in the respective test subjects. Researchers are also increasingly making the data they obtain available to colleagues, who can then use it to work on completely different matters. "And this is exactly what we did in our study," says Dr. Anna Aschenbrenner from the LIMES Institute at the University of Bonn and member of the ImmunoSensation² Cluster of Excellence.


Publication

Lorenzo Bonaguro, Maren Köhne, Lisa Schmidleithner, Jonas Schulte-Schrepping, Stefanie Warnat-Herresthal, Arik Horne, Paul Kern, Patrick Günther, Rob ter Horst, Martin Jaeger, Souad Rahmouni, Michel Georges, Christine S. Falk, Yang Li, Elvira Mass, Marc Beyer, Leo A. B. Joosten Mihai G. Netea, Thomas Ulas, Joachim L. Schultze and Anna C. Aschenbrenner: CRELD1 modulates homeostasis of the immune system in mice and humans. Nature Immunology;
https://www.nature.com/articles/s41590-020-00811-2

Media contact

Dr. Anna C. Aschenbrenner

LIMES-Institut der Universität Bonn

Tel.: +49 (0228) 73-62777 or +49 (0228)
4330-2690

E-mail: a.aschenbrenner@uni-bonn.de

Related news

Tracking glioblastoma cell spread in human brain tissue

News categories: Publication

Core2Edge: How tumor cells conquer the brain

Glioblastoma is an aggressive brain tumor that infiltrates deep into the surrounding brain tissue. Even after surgery, tumor cells remain in the brain and the tumor recurs. Bonn researchers have now developed Core2Edge, a model based entirely on human tissue that captures these hard-to-access infiltration zones at the tumor margin. The model enables investigation of the invasive front and direct assessment of new drug candidates in human tissue - without the need for animal testing. The study of the Brain Tumor Translational Research Group has now been published in Nature Protocols.
View entry
Mikrochip zur Wiederherstellung zentralen Sehvermögens bei fortgeschrittener Makuladegeneration.

News categories: Publication

Approval of a Novel Retinal Implant Technology

A novel retinal implant is offering people with geographic atrophy the opportunity to regain part of their central vision for the first time. Geographic atrophy is a severe late stage of age-related macular degeneration. An international research team led by Prof. Frank G. Holz of the UKB and the University of Bonn demonstrated in an international clinical trial that the majority of participants experienced significant improvements in visual acuity. The novel retinal implant technology has now received approval for routine clinical use in Europe, making it available beyond clinical trials.
View entry
Authors

News categories: Publication

The Gut as a Key Player in Immunotherapy for MS

B-cell depletion therapies, in which B cells of the immune system, which may drive disease activity in multiple sclerosis (MS), are temporarily removed, have contributed significantly to improved treatment for patients in recent years. Researchers from Bonn, along with their collaborators, have uncovered a previously unknown mechanism through which B-cell depletion therapies contribute to a better disease course in patients with MS. Surprisingly, the treatment appears to exert part of its beneficial effect by mobilizing regulatory immune cells that naturally reside in the gut.
View entry

Back to the news overview